Dorsavi Ltd. · ASX:DVL
Dorsavi — Shareholder Meeting (November 2020)
16 slides from Dorsavi's shareholder meeting presentation, Nov 27, 2020
Slide 1: 2020 Annual General Meeting – Chairman's Address and CEO Presentation
27 November 2020 The Manager, Listings ASX Limited Company Announcements Office Level 4 Exchange Centre 20 Bridge Street SYDNEY NSW 2000 Dear Sir/Madam 2020 Annual General Meeting – Chairman’s Address and CEO Presentation We attach a copy of the Chairman’s address and the CEO’s presentation to be de
Slide 2: Opening Address by Mr Greg Tweedly, Chairman
DORSAVI LTD AGM 27 NOVEMBER 2020 OPENING ADDRESS BY MR GREG TWEEDLY, CHAIRMAN, DORSVI LTD ADDRESS BY GREG TWEEDLY 2020 has been a challenging year in many ways, none more significant than having to navigate through a global pandemic. The dorsaVi business has shown great resilience in working through
Slide 3: Chairman's address continued: markets, deals and partners
Our CEO has returned to Australia from close to 3 years in the US and is confident he can continue to build on the remote relationships with major corporates that he developed during his time in the US. The company’s non-executive directors received shareholder approval at the 2019 AGM, to accept op
Slide 4: Corporate focus on technology-based solutions to reduce health costs
with corporate executive teams prioritising projects that provide efficient, technology-based solutions aiming to reduce health costs and minimise injuries in the workplace. dorsaVi’s data driven solutions have been shown to improve health outcomes in clinical trials and reduce injuries in workplace
Slide 5: CEO AGM Presentation
CEO AGM Presentation 27 NOVEMBER 2020
Slide 6: Important Information and Disclaimer
IMPORTANT INFORMATION AND DISCLAIMER Not financial product advice or offer This presentation does not constitute an offer of securities or investment, legal, taxation or other advice and the presentation does not take into account your investment objectives, financial situation or particular needs.
Slide 7: Executive Summary
EXECUTIVE SUMMARY • Revenue generating medical device company commercialising innovative motion analysis technologies that Commercial stage wearables accurately measures muscle activity and movement device company • Technology has attracted blue-chip customers including Amazon, Caterpillar and Heath
Slide 8: Unique, Validated and Proven Technology
UNIQUE, VALIDATED AND PROVEN TECHNOLOGY WHAT IS OUR TECHNOLOGY? Wearable sensors that measure movement and muscle activity at 200 frames per second paired with patented algorithms HOW DOES IT WORK? Movement - measured through use of accelerometers, magnetometers and gyroscopes Muscle - measured thro
Slide 9: Successful Transition from Low to High Margin Revenue
SUCCESSFUL TRANSITION FROM LOW TO HIGH MARGIN REVENUE RECURRING REVENUE, FY18 FY19 FY20 PRODUCT-LED BUSINESS Consulting-led revenue Transitory phase, developing Improved and enhanced product, model, lower margin, high product, dual focus on increased focus on product-led ü Recurring revenue model le
Slide 10: Increasing Recurring Revenue Underpins dorsaVi's Strategy
INCREASING RECURRING REVENUE UNDERPINS DORSAVI’S STRATEGY Recurring revenue (A$k) Recurring revenue as a % of total +33% CAGR +49% (absolute) 1,504k 74% 1,281k 51% 856k 25% FY18 FY19 FY20 FY18 FY19 FY20 Page 6 Source: Company financials
Slide 11: Targeting Two Valuable Target Markets in the US
TARGETING TWO VALUABLE TARGET MARKETS IN THE US Core product lines Workplace Clinical HOSPITAL IN CORPORATE INSURANCE PHYSIO THE HOME aka Physical Therapy Contract with large, labour- Contract with insurance Provision of sensors to Provision of sensors from intensive operating companies to reduce ph
Slide 12: Well Positioned to Deliver Next Phase of Growth
WELL POSITIONED TO DELIVER NEXT PHASE OF GROWTH Building blocks now ..to deliver strong ..and take advantage firmly in place.. operating leverage.. of strong tailwinds ü Years of R&D to optimise ü Recurring revenue with ü Increasing corporate technology low customer churn focus to reduce workplace i
Slide 13: Clear Plan to Cash Flow Positive in FY22
CLEAR PLAN TO CASH FLOW POSITIVE IN FY22 Cash FY21 FY22 flow Increase inflows – dorsaVi is targeting >25% recurring revenue growth in FY21 (see next page for further details) § Build recurring revenue § Monetisation of pilot products § Secure new deals with new § Diversify sales channel § Expand sal
Slide 14: Targeting Recurring Revenue Growth of >25% in FY21
TARGETING RECURRING REVENUE GROWTH OF >25% IN FY21 WITH SIGNIFICANT WHITESPACE AHEAD Build recurring revenue Grow channel partners New global platform Continue growing revenue with proven Focus on strategic agreements with key In talks with S&P500 customers, aided by product, supported by strong tai
Slide 15: Investment Highlights
INVESTMENT HIGHLIGHTS SCALABLE WORLD-CLASS TECHNOLOGY Tailored motion sensor products developed over several years, uniquely available to the workplace and clinical market, and differentiated by its global approvals (FDA, TGA, CE Mark) SUCCESSFUL TRANSITION TO HIGHER MARGIN, PRODUCT-LED MODEL Strong
Slide 16: Contact us: Andrew Ronchi, Chief Executive Officer
Contact us: Website: www.dorsavi.com Andrew Ronchi Chief Executive Officer Social media: LinkedIn: dorsaVi T: +61 417 882 267 Twitter: @dorsavi E: ar@dorsaVi.com